Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots

Shares of Pfizer, Moderna, and Novavax declined significantly on Friday, with Moderna down over 7% and Pfizer over 3%, following a Washington Post report that Trump administration health officials plan to present claims linking Covid vaccines to 25 child deaths to a key CDC advisory panel. This report, based on unverified data from the VAERS system, emerges as HHS Secretary Robert F. Kennedy Jr. actively seeks to revise U.S. vaccine policy, despite vaccine manufacturers asserting the rigorous monitoring and established safety of their mRNA products.

Analysis

Shares of key Covid-19 vaccine manufacturers experienced significant declines, with Moderna (MRNA) falling over 7% and Pfizer (PFE) over 3%, directly following a report that Trump administration health officials intend to link their vaccines to 25 child deaths in a presentation to a critical CDC advisory panel. The claim's credibility is questionable as it appears to be based on the Vaccine Adverse Event Reporting System (VAERS), which contains unverified, self-reported data that requires scientific investigation to establish causality. This event is not isolated, but rather part of a broader shift in U.S. vaccine policy under HHS Secretary Robert F. Kennedy Jr., who has already limited vaccine recommendations and publicly supported statements questioning the safety of mRNA technology. While Moderna has responded by affirming its vaccine's safety, citing rigorous monitoring and a lack of new safety concerns from global regulators, the market is pricing in the heightened regulatory and political risk. The negative sentiment is most pronounced for Moderna, reflecting its greater dependence on its mRNA vaccine platform compared to the more diversified Pfizer.

Key Decisions for Investors

• Investors should monitor the upcoming CDC advisory panel meeting for the official response to these claims, as the outcome will determine the tangible impact on vaccine recommendations and insurer coverage, which is the primary risk driver.
• Recognize the differential vulnerability among vaccine makers; Moderna's sharper stock decline of over 7% highlights its concentrated exposure to its mRNA Covid vaccine, making it more sensitive to policy shifts and negative sentiment than the more diversified Pfizer.
• Factor in a sustained period of political and regulatory overhang for the sector, as the actions of the HHS Secretary signal a persistent effort to revise U.S. vaccine policy, likely leading to continued share price volatility for PFE, MRNA, and NVAX.